Literature DB >> 31589745

The 2018 ESC/ESH hypertension guideline and the 2019 NICE hypertension guideline, how and why they differ.

Terry McCormack1, Rebecca J Boffa2, Nicholas R Jones3, Serena Carville2, Richard J McManus3.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31589745     DOI： 10.1093/eurheartj/ehz681

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  8 in total

1.  Variation in hypertension clinical practice guidelines: a global comparison.

Authors:  Richu Philip; Thomas Beaney; Nick Appelbaum; Carmen Rodriguez Gonzalvez; Charlotte Koldeweij; Amelia Kataria Golestaneh; Neil Poulter; Jonathan M Clarke
Journal:  BMC Med       Date:  2021-05-12       Impact factor: 8.775

2.  Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk: A Markov Modeling Study.

Authors:  Margaret Constanti; Christopher N Floyd; Mark Glover; Rebecca Boffa; Anthony S Wierzbicki; Richard J McManus
Journal:  Hypertension       Date:  2020-12-21       Impact factor: 10.190

3.  Comparison of the antihypertensive efficacy of morning and bedtime dosing on reducing morning blood pressure surge: A protocol for systemic review and meta-analysis.

Authors:  Peng Zhang; Mei-Ying Jin; Xu-Yu Song; Zhao Wang; Yue-Hua Jiang; Chuan-Hua Yang
Journal:  Medicine (Baltimore)       Date:  2021-02-05       Impact factor: 1.817

4.  Associations of the systolic and diastolic components of orthostatic hypotension with markers of cardiovascular risk in older men: A cross-sectional analysis from The British Regional Heart Study.

Authors:  Artaza Gilani; Sheena E Ramsay; Stephen P Juraschek; Olia Papacosta; Lucy T Lennon; Peter H Whincup; Sasiwarang Goya Wannamethee
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-16       Impact factor: 3.738

5.  Nebivolol is more effective than atenolol for blood pressure variability attenuation and target organ damage prevention in L-NAME hypertensive rats.

Authors:  Julieta S Del Mauro; Paula D Prince; Yanina Santander Plantamura; Miguel A Allo; Luciano Parola; Nahuel Fernandez Machulsky; Marcela A Morettón; Eliana P Bin; Germán E González; Facundo M Bertera; Andrea Carranza; Gabriela Berg; Carlos A Taira; Martín Donato; Diego A Chiappetta; Ariel H Polizio; Christian Höcht
Journal:  Hypertens Res       Date:  2021-02-22       Impact factor: 3.872

6.  Prospective multicentric validation of a novel prediction model for paroxysmal atrial fibrillation.

Authors:  Constanze Schmidt; Sebastian Benda; Patricia Kraft; Felix Wiedmann; Sven Pleger; Antonius Büscher; Dierk Thomas; Rolf Wachter; Christian Schmid; Roland Eils; Hugo A Katus; Stefan M Kallenberger
Journal:  Clin Res Cardiol       Date:  2020-11-19       Impact factor: 5.460

7.  Inverted U-shaped relationship between body mass index and multivessel lesions in Chinese patients with myocardial infarction: a cross-sectional study.

Authors:  Dandan Sun; Wei Li; Hongmin Zhang; Yafen Li; Qingyun Zhang
Journal:  J Int Med Res       Date:  2020-07       Impact factor: 1.671

8.  A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.

Authors:  Zhongchao Wang; Dewei Zhang; Shengming Wang; Yanhua Jin; Jianbo Huan; Yue Wu; Cheng Xia; Zhe Li; Xingshun Qi; Duanzhen Zhang; Xiumin Han; Xianyang Zhu; Ying Qu; Qiguang Wang
Journal:  Med Sci Monit       Date:  2020-09-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.